Verition Fund Management
ADCT icon

Verition Fund Management’s ADC Therapeutics ADCT Stock Holding History

Verition Fund Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.2K Buy
+40,330
New +$118K ﹤0.01% 1980
2023
Q3 		– Sell
-14,649
Closed -$31.5K – 2306
2023
Q2 		$31.5K Buy
14,649
+3,408
+30% +$7.66K ﹤0.01% 2055
2023
Q1 		$21.9K Buy
+11,241
New +$41.5K ﹤0.01% 2006

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Verition Fund Management's ADCT Position: Q2 2026 in Review

Verition Fund Management opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 40,330 shares worth $43.2K. The stake represents ﹤0.01% of the portfolio and ranks #1980 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in ADCT as recently as Q2 2023.

Verition Fund Management first reported a position in ADCT in Q1 2023 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Verition Fund Management held 40,330 shares of ADC Therapeutics worth $43.2K as of Q2 2026.
  • ADC Therapeutics was a new Verition Fund Management position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1980 holding.
  • Verition Fund Management first reported a position in ADC Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.